Physician profile
Mark Robert Schwartz
NPI 1760453567
$1,533.46
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $18.31 · 2021: $256 · 2022: $451 · 2023: $659 · 2024: $14.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $481.05 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Davol INC. | $411.14 | 2020-2023 | Xenmatrix Ab Surgical Graft |
| Integra Lifesciences Corporation | $212.49 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $115.25 | 2021 | |
| Zimmer Biomet Holdings, INC. | $107.99 | 2019 | |
| Intuitive Surgical, INC. | $47.43 | 2021 | |
| Acera Surgical, INC. | $35.78 | 2022 | |
| Ethicon US, LLC | $23.40 | 2022 | |
| Innocoll Pharmaceuticals Limited | $18.66 | 2021 | |
| Axonics, INC. | $14.33 | 2021 | |
| Solventum Corporation | $14.20 | 2024 | V.A.C. Veraflo, V.A.C.Ulta, Abthera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.79 | 2019 | |
| Abbvie INC. | $13.17 | 2021 | |
| Misonix INC | $12.51 | 2021 | |
| Celgene Corporation | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.